

Form 39A [See Rule 150E(f)] Under the Drugs and Cosmetics Act 1940 and the Rules thereunder

Sample Name #	ROXITHROMYCIN TABLETS IP 150 mg	Report No.	[REDACTED]
		Mfg. Lic. No.#	
Mfd. By#	NA		
Supplied By#	NA	Date of Receipt	16/09/2024
Submitted By Address	MEGHALAYAN MEDICAL DRUGS AND SERVICES NEW COLONY SHILLONG, DHS LAITUMKHAH, OFFICE OF THE MANAGING DIRECTOR MMSDSL EAST	Sample Qty.#	60 TABLETS
		Batch Size#	NA
		Mfg.Date#	12/2022
Ref. No.#	N/A	Exp.Date#	11/2025
Batch No.#	MMSDSL/QC/-0477		

NS

Date of Start of Analysis : 16/09/2024

Date of Completion of Analysis : 27/09/2024

RESULTS OF ANALYSIS

Reference to Protocol : IP 2022

DESCRIPTION : Sky blue colour capsule shape biconvex film coated tablet scored on both side.

S.No.	PARAMETERS/TEST	RESULTS	LIMIT	
1	IDENTIFICATION	Complies		
2	AVERAGE WEIGHT	309.62 mg		
3	UNIFORMITY OF WEIGHT	Within Limit	± 5.0%	
4	DISSOLUTION (BY HPLC)	89.42% to 92.54%	Q NLT 70%	
5	ASSAY	Each film coated tablet contains.		
COMPOSITION		RESULTS	LABEL CLAIM	LIMITS
ROXITHROMYCIN IP		141.90 mg	150 mg	135mg to 165mg
				IP-2022

Remarks : In the opinion of the undersigned, the sample referred above is of standard quality as defined in the Drugs Act 1940 and Rules made thereunder for the reasons given below as per IP 2022
Sample Consumed in testing

*****END OF REPORT*****

Represents Customer Defined Fields

Date of Issue : 13/11/2024

Note:-

1. Sample (s) not drawn by us unless otherwise stated.
2. Total liability of our analytical division is limited to the invoiced amount.
3. Sample will be destroyed after one month from the date of issue of test certificate unless otherwise specified.
4. Test certificate in full or parts shall not be used for promotional or publicity purpose.
5. Result given in report is related to sample tested only.